Project Grant HT94252410142
Award Date
5/1/24
Completion Date
4/30/26
Dollars Obligated
$983K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
The Johns Hopkins University was awarded a $1,623,356 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2023 to July 31, 2026 to develop CHMP7 antisense oligonucleotide (ASO) therapy to repair nuclear pore and TDP43 dysfunction in sporadic and familial forms of amyotrophic lateral sclerosis (ALS). The Military Medical Research and Development program supports basic, applied, and...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $798,272 project grant to The Johns Hopkins University on March 15, 2025. The grant will fund a 2-year research project titled "Testing the Use of WNT Inhibitors as a Therapeutic to Reverse TDP-43 Dysfunction in ALS." The research aims to develop novel therapeutic approaches for amyotrophic lateral sclerosis (ALS) by investigating the use of WNT inhibitors to address TDP-43 protein...
The Johns Hopkins University received a $2,455,671.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop an AAV-based gene therapy for amyotrophic lateral sclerosis (ALS). The award, effective June 1, 2024 through May 31, 2027, will enable Johns Hopkins to conduct innovative biomedical research and advance therapeutic solutions for this neurological disorder. The federal grant funding supports the university's...
The Johns Hopkins University was awarded an $818,750 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The award will support research into RNA-based modulation of TDP-43 mislocalization in ALS/FTD with uridine analogs from September 15, 2022 to September 14, 2024. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...
This $1,137,301 federal Project Grant awarded by the Defense Health Agency on July 1, 2024 supports The Johns Hopkins University's work on "MULTI-MODAL, REMOTE TRACKING OF ALS PROGRESSION USING NOVEL DIGITAL BIOMARKERS" through June 30, 2026. The grant is funded under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The project aims to develop...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $855,728 to The Johns Hopkins University to identify abnormally regulated lipid pathways in human motor neuron and fly models, with the goal of developing a new pharmacological drug candidate. The award period runs from Sep 1, 2024 to Aug 31, 2026. As a leading research university, Johns Hopkins has a strong track record of federal grant...
This Project Grant award, with a total funding amount of $931,500.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports advanced biomedical research to transform healthcare for military service members, veterans, and the broader public. Specifically, this award will fund research by The Johns Hopkins University to develop a RIPK2 inhibitor for the treatment of amyotrophic lateral sclerosis...
The Department of the Army Medical Command awarded a $319,938 project grant under the Military Medical Research and Development (CFDA 12.420) program to The Johns Hopkins University. The grant, with a performance period from September 1, 2024 to August 31, 2026, will fund a large-scale MRI-based study to determine multiple sclerosis-specific atrophy phenotypes. This research aims to transform healthcare for military service members and the broader public by advancing the understanding and...
The Department of Defense's Defense Health Agency awarded a $2,058,746 Project Grant to The Johns Hopkins University to study the effects of psilocybin in patients with amyotrophic lateral sclerosis (ALS). The grant, awarded on September 30, 2024 under the Military Medical Research and Development program (CFDA 12.420), will fund this research project over a 3-year period ending on September 29, 2027. The Johns Hopkins University is a leading private research institution with extensive...
The Johns Hopkins University will receive $966,758 under a Project Grant award from the Department of the Army Medical Command. The grant is part of the Military Medical Research and Development program administered under Assistance Listing Number 12.420. Under this three-year award ending in August 2025, The Johns Hopkins University will investigate circulating central nervous system cell-derived extracellular vesicle based biomarkers to identify neurodegeneration and glial activation in...